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Abstract
Purpose To study clinical patterns of disease onset in
monogenic retinal dystrophies (MRD), using an epidemio-
logical approach.
Methods Records of patients with MRD, seen at the
University Eye Hospital Tuebingen from 1994 to 1999,
were selected from a database and retrospectively reviewed.
For analysis, patients were divided into 2 groups by
predominant part of visual field (VF) involvement: group
1 (predominantly central involvement) included Stargardt
disease (ST), macular dystrophy (MD), and central areolar
choroidal dystrophy (CACD), and group 2 (predominantly
peripheral involvement) included Bardet–Biedl syndrome
(BBD), Usher syndrome (USH) I and II, and choroideremia
(CHD). Age, sex, age of first diagnosis, age of visual acuity
(VA) decrease and VF emergence, night blindness and
photophobia onset, types of VF defects and age of its onset,
color discrimination defects and best corrected VA were
analyzed.
Results Records of 259 patients were studied. Men were
more prevalent than women. Mean age of the patients was
47.2 (SD=15.6) years old. Forty-five patients in the first
group and 40 in the second were first diagnosed between 21
and 30 years of age. Ninety-four patients in the first group
had VA decrease before 30 years of age; in the second
group, 68 patients had VA decrease onset between 21 and
40 years of age. Forty-four patients in the first group
noticed VF at an age between 21 and 30 years, and 74
patients between 11 and 30 years in the second group.
Central scotoma was typical for the first group, and was
detected in 115 patients. Concentric constriction was typical
for the second group, and was found in 81 patients. Half of
patients in both groups preserved best-corrected VA in the
better eye at a level of 20/40 or better; 7% in the first group
and 6% in the second group were registered as legally blind
according to WHO criteria, having VA <1/50 or VF <5°.
Diagnosis frequency was USH I and II—34%, ST—31%,
MD—18%, CHD—14%, BBD—5%.
Conclusions An epidemiological approach to the estima-
tion of the disease onset of various subtypes of monogenic
retinal degenerations will be useful for detection of disease
duration, its prognosis, rehabilitation and the researching of
future treatment possibilities.
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Introduction
Low vision and blindness are important public health
problems not only in Germany, but worldwide [13]. Globally,
in 2002 more than 161 million people were visually impaired,
of whom 124 million had low vision and 37 million were
blind [19]; 12.8% of the European population had low vision
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and 15.5% visual impairment [18]. According to the German
Federation of Blind and Visually Impaired People, the
number of blind people in Germany is about 145,000 and
the number of partially sighted people is approximately
500,000 [8, 9].
The two most common retinal degenerative diseases that
result in blindness secondary to photoreceptor loss are age-
related macular degeneration and retinitis pigmentosa.
Retinitis pigmentosa is more severe, and its symptoms
appear earlier in life, but age-related macular degeneration
is more prevalent [17].
Currently, there is no therapy that stops the evolution of
monogenic retinal dystrophies [6, 17]. As the knowledge of
molecular genetics and molecular biology increases, it may
become possible to develop new treatment strategies [3]
that will be based on pharmaceutical interventions such as
topical treatment with alpha2-agonist [14], gene therapy
such as RPE65 gene replacement [4], cell transplantation
[2], and artificial retinal implants [20]. Due to this, a
screening of monogenic retinal degenerations (MRD) at age
at risk and identifying affected individuals in the early
stages of the disease is necessary, and this shows the
importance of epidemiological studies focused on disease
and blindness onset estimation in MRD.
A retrospective longitudinal study of hereditary retinal
degenerations (HRD) performed in Northern France
showed the importance of such studies for establishment
of HRD prevalence as well as the age of its diagnosis in the
population [15]. Earlier epidemiological studies have been
based on the information received from social services, and
were focused on the estimation of the onset of blindness,
but not of the disease itself [9, 10]. Disease and blindness
onset in monogenic retinal degeneration need to be further
investigated using an epidemiological approach as in the
following study.
Materials and methods
Data from 3,787 patients with monogenic retinal degener-
ations, seen at the University Eye Hospital Tuebingen from
1994 to 1999, were stored in an RP-clinical access-based
database. Records of 259 patients with hereditary retinal
dystrophies were selected for the study from this database
according to the inclusion criteria (diagnosis). Two groups
of hereditary retinal dystrophies were selected for our
study: the first group included pigment epithelial disorders
(Stargardt and central areolar choroidal dystrophy (CACD))
and macular dystrophies with different age structure (Best’s
disease, pseudovetilliform macular dystrophy, pattern mac-
ular dystrophy and progressive macular dystrophy); the
second group included syndromic degenerative diseases
(Bardet-Biedl, Usher Syndrome I and II, choroideremia). A
time frame from 1994 to 1999 was chosen for the study.
During this period all clinical data was collected in a highly
standardized manner, using an electronic database system.
The first visit data were retrospectively analyzed,
including general information, disease history and data
about color discrimination defects and best-corrected VA of
these patients. General information contained the main
demographic characteristics of the study population: age,
sex and nationality. Age of the patients was estimated as the
age when they had their first visit to the special clinic for
inherited retinal degenerations in Tuebingen. Disease
history included information about disease onset and
evolution of clinical appearance of the disease over time,
such as the age of first diagnosis, age of visual acuity (VA)
decrease, night blindness and photophobia onset, and types
of VF defects and age of patient at its onset, which were
reported by the patient. Age at onset of symptoms was
defined as the age at which these symptoms were either first
reported by the patient and/or diagnosed by the ophthal-
mologist. Age at first diagnosis was defined as the age at
which the first correct diagnosis was made, as indicated by
the patient. Final diagnosis was recorded as a diagnosis that
was established during the last visit of the patient within the
chosen follow-up period.
Diagnosis was established by a team of four senior
resident ophthalmologists at the Eye University Hospital
Tuebingen, and was based on a comprehensive analysis of
medical history, clinical investigation including best-
corrected visual acuity, Goldmann or semiautomatic kinetic
perimetery, color testing (Panel D15 test), examination of
anterior segment and funduscopy, Ganzfeld ERG (in every
patient) and mfERG (in selected patients) according to
current ISCEV protocols [7]. Only some of the patients
could be genetically tested, and in a fraction of them it was
possible to verify the diagnosis genetically.
Types of VF defects, color discrimination defects and
best-corrected VAwere obtained from the results of clinical
examination. For the purpose of analysis, patients were
divided into two homogenous groups according to predom-
inant type of visual field defect: group 1 (with predomi-
nantly central involvement)including Stargardt disease,
macular dystrophy, and CACD, and group 2 (predominant-
ly peripheral involvement) including Bardet-Biedl syn-
drome, Usher Syndrome I and II, and choroideremia.
The study was designed with respect to ethical standards
laid down in the 1964 Declaration of Helsinki. The study
protocol was reviewed and approved by the Ethics
Commission of the Medical Faculty, Eberhard-Karls Uni-
versity Tuebingen, Germany. All information was handled
with the special guarantee of confidentiality in order to
avoid unwanted back-tracing of participants.
For further analysis, data was extracted from an MS
Access 2000-based RP-clinical database using Structured
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Query Language (SQL) selection, and transferred to an
Excel spreadsheet that was used for data management.
Statistical analysis was performed using SPSS 11.00 for
Windows. Descriptive statistics, including mean and
standard deviation and frequency calculation, were used
for data analysis. Data concerning age distribution, age
at first diagnosis, age of night blindness, photophobia
and VA decrease onset, and age of emergence of VF
defects were further stratified by diagnosis, which made
it possible to see the contribution of each diagnosis in
each age group; VA distribution data was stratified by
age. Frequency of diagnosis and blindness was defined
as the number of patients with this condition divided by
the study population.
Results
General information
General information about the study population included
data about age, gender and nationality. Records of 259
patients were studied. In total, group 1 (predominantly
central involvement) included 134 patients and group 2
(predominantly peripheral involvement) 125 patients.
Sex distribution: sex distribution analysis revealed that
in both groups men predominated in comparison with
women. The same trend was revealed when stratifying the
data according to diagnosis in both groups (Figs. 1, 2a).
Group 1 included 87 male and 47 female patients; group 2
included 72 male and 53 female patients. In the subgroup of
patients with choroideremia, men are prevalent, as the
disease is inherited via an X-linked recessive mechanism.
At the same time, our data contained women who were
mostly obligatory carriers of the disease with or without
symptoms, and one case was diagnosed with choroider-
emia. The distribution of women in the choroideremia
subgroup is shown in Fig. 2b.
Age distribution
Age distribution analysis showed that patients between 21
and 40 years old (n=53) represented the majority in group
1. The age group 41–60 years old included 42 patients in
group 1; age groups 0–20, 61–80, and over 80 were
presented by two, 34 and three patients respectively
(Fig. 3a)
Fifty-two patients in group 2 were between 41 and
60 years old, 40 between 21 to 40 years old; 26 patients
were aged between 61 and 80 years old, and there were no
patients older than 80 (Fig. 3a). Mean age for the entire
study population was 47.2 years old (SD=15.6).
A stratification of subgroups with specific diseases
according to contribution of certain age groups of the
patients is shown on the Fig. 3b.
Nationality distribution of the patients: German patients
were predominant in both groups; in group 1 Germans
represented 87 patients, and in group 2 76 patients. Forty-
seven and 49 patients respectively originated from Central
European countries.
History of the disease data
History of the disease data incorporated age at first diagnosis,
age of visual acuity decrease, age of night blindness,
photophobia onset and age of visual field defects emergence.
Age at first diagnosis showed the same trend for groups
1 and 2. In group 1 we observed that ten patients were
diagnosed for the first time before 10 years old, 27 between
11 and 20 years old, 45 between 21 and 30, 17 between 31
55
17 15
34
8
5
0
10
20
30
40
50
60
Stargardt Macular dystrophy CACD
N
o.
 o
f p
at
ie
nt
s
Diagnosis
male
female
Fig. 1 Sex distribution of patients in group 1 (predominantly central
retina involvement), stratified by diagnosis
7
10
30
25
6
8
28
11
0
5
10
15
20
25
30
35
Bardet-Biedl Usher I Usher II Choroideremia
N
o.
 o
f p
at
ie
n
ts
Diagnosis
male 
female
30%
60%
10% obligatory carrier with
symptoms
obligatory carrier
without symptoms
diagnosed with a
disease
a
b
Fig. 2 a Sex distribution of the patients in Group 2 (predominantly
peripheral involvement), stratified by diagnosis. b Distribution of
women in choroideremia subgroup
Graefes Arch Clin Exp Ophthalmol
and 40, 27 between 41 and 50, and eight patients between
51 and 60 years of age(Fig. 4a). In group 2, 17 patients
were first diagnosed before age 10, 31 between 11 and
20 years old, 40 between 21 and 30 , 23 between 31 and 40,
12 between 41 and 50, and two were first diagnosed after
51 years of age (Fig. 4a).
Age at first diagnosis stratified by diagnosis is shown in
Fig. 4b.
Night blindness onset is one of the most important signs
for detecting the disease onset of monogenic retinal
degenerations. Information about night blindness onset
was separately analyzed for groups 1 and 2. Forty-nine
patients in group 1 first noticed night blindness when they
were between 41 and 50 years old, 35 patients in this group
noticed the presence of night blindness between 11 and
20 years of age, and 11 patients each between 1 and 10 and
31 and 40 years of age; the remaining three patients first
experienced night blindness between 51 and 60 years of
age. A different trend was observed in group 2: 38 patients
in this group first noticed the presence of night blindness
before 10 years of age, 44 between 11 and 20, 21 between
21 and 30 years of age, 11 between 31 and 40 years of age,
five patients each between 41 and 50, and three between 51
and 60 years old (Fig. 5a).
A stratification of age of night blindness onset according
to the disease is demonstrated in Fig. 5b.
Photophobia is one of the middle-stage symptoms of
monogenic retinal degeneration. A similar tendency was
observed in patients of both groups; the majority in both
groups first noticed photophobia when they were younger
than 30 years old. In group 1, ten patients first reported
photophobia before the age of 10, 27 between 11 and 20 years
old and 45 between 21 and 30 years old; of the remaining 52
patients, 17 patients first recognized photophobia between 31
and 40 years old, 27 between 41–50, and eight after the age of
51 years (Fig. 6a). In group 2, 17 patients first reported
photophobia before the age of 10, 31 between 11 and
20 years old and 40 between 21 and 30 years old. 23 patients
reported photophobia between 31 and 40 years of age, 12
between 41 and 50 years old, and two patients after 50 years
old (Fig. 6a). Both groups were quite similar with respect to
photophobia onset, and the mean age of onset for both
groups was 26 years old (SD=15).
A stratification of age of photophobia onset in accor-
dance to diagnosis is shown on Fig. 6b.
The age of onset of visual acuity decrease had different
trends in the two groups. The data were collected for right
and left eyes; results showed that there was no difference
found in onset of visual acuity decrease between right and
left eyes. In group 1, the majority of patients (n=94)
noticed a decrease in visual acuity before 30 years old: 30
patients before 10, 33 between 11 and 20 years of age, and
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31 between 21 and 30 years old. The remaining 40 patients
first noticed or were diagnosed with decreased visual
acuity after 31 years of age: 16 patients between 31 and
40 years old, 22 between 41 and 50, and two patients after
51 years of age (Fig. 7a). In group 2, 36 patients had
visual acuity decrease between 21 and 30 years old, and
32 between 31 and 40 years old. 36 patients noticed visual
acuity decrease before 20 years old: 19 of them before 10,
and 17 patients between 11 and 20 years old. A relatively
high number of patients (n=17) recorded visual acuity
decrease between 41 and 50 years of age and four patients
after 51 years of age (Fig. 7a).
Age of onset of visual acuity decrease stratified by
diagnosis is shown in Fig. 7b.
It was observed that in both groups visual field defects
emergence was reported by the patient before the age of
30 years. In the first group, 44 patients reported emergence
of visual field defects at an age between 21 and 30 years
old, 31 between 11 and 20 years old, and 26 between 41
and 50 years old. The remaining patients reported early
visual defects appearance: ten below 10 years of age, eight
between 31 and 40 years old, and 15 between 51 and
60 years old (Fig. 8a). In group 2, 38 and 36 patients
presented visual field defects at age periods 11–20 and 21–
30 years old respectively; 23 patients in this group first
observed visual field defects at an age before 10 years old,
22 at an age between 31 and 40, and six in the 41–50 age
range. No patients in group 2 reported first onset of visual
field defects beyond the age of 50 years (Fig. 8a). Visual
defects appearance trends were quite similar between the
groups, and mean age onset for both groups was 26 years
old (SD=14.5).
A stratification of emergence of visual defects according
to the diagnosis is shown in Fig. 8b.
Results concerning clinical data
The clinical data analyzed included best-corrected VA
(BCVA), types of visual field defects and color perception
problem diagnoses. BCVA was measured for both eyes of
the patients. Visual acuity better than or equal to 20/40 was
detected in 124 eyes in group 1 and 140 eyes in group 2;
best-corrected visual acuity lower than 20/40 and higher
than 20/200 was observed in 81 eyes in group 1 and 83 in
group 2; lower than 20/200 was determined in 43 eyes from
group 1 and 15 from the second group (Fig. 9a). We
defined legally blind patients as having visual acuity lower
than 20/400 or visual field less than 5° in the better eye,
according to the WHO definition [16]. Twenty eyes in
group 1 and 12 eyes in group 2 had a visual acuity that
corresponded to the criteria for legal blindness (Fig. 9a).
Overall, 7% of patients in group 1 and 6% in the second
group were registered as legally blind.
Best-corrected visual acuity stratified by age is shown
on Fig. 9b.
A stratification of BCVA by age showed an interesting
pattern: BCVA higher or equal to 20/40 was observed in
35% of patients 41–60 years of age. Half of the patients
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with BCVA less than 20/40 but higher than 20/200 were in
the 21–40 age range, while the other half was in the 61–80
age range. Forty percent of patients in the age group 41–60
and 39% in 21–40 had visual acuity less than 20/200.
Thirty-seven percent of patients in age group 21–40 and
36% in age group 41–60 were registered as legally blind
(Fig. 9b).
The types of visual field defects are as important as the
age of their onset, since they define the level of decrease of
the patient’s quality of life and the effectiveness of further
rehabilitation. Patients from group 1 had a higher frequency
of central scotoma (n=115), whereas concentric constric-
tion (n=13) and ring scotoma (n=6) were detected less
frequently. By contrast, in group 2 concentric constrictions
were observed in 81 patients, central scotoma in 34, and
ring scotoma in ten patients.
Both groups showed a quite similar tendency concerning
the presence of color perception problems. In group 1, color
perception problems were present in 68 patients and absent
in 68, while in group 2 color perception defects were
detected in 60 and were absent in 54.
The frequencies of main diagnoses in the study
population were analyzed for both groups together. Diag-
nosis frequency was Usher I and II 34%, Stargardt disease
31%, macular dystrophy 10%, CACD 8%, and Bardet-
Biedl syndrome 5%.
Eighty-two patients (out of a total of 134) in group 1 and
89 patients (out of a total of 125) in group 2 were
genetically tested in the Genetic Department of the
University Eye Hospital Tuebingen. In the first group, 51
patients were genetically verified to have Stargardt disease;
ten macular dystrophy, including six patients with Best’s
disease; and 21 central choroidal dystrophy (CACD). In the
second group, six patients were genetically verified to have
Bardet-Biedl syndrome; 18 Usher syndrome I; 51 Usher
syndroms II, and 14 patients had choroideremia.
Discussion
The results of the current study suggest that monogenic
retinal degenerations are more frequent among men than
among women. This corresponds to the conclusion formed
by Krumpaszky in his study of inherited retinal degener-
ations in the Baden-Württemberg region in 1999 [10].
This may be due to X-recessive inheritance mechanism of
some of the diseases, such as macular dystrophy and
choroideremia.
The majority of patients in the study population were
first diagnosed by an ophthalmologist with monogenic
retinal dystrophy at an age between 11 and 30 years old,
which is in line with the results obtained by Tsujikawa et al.
in the study of age onset curves of retinitis pigmentosa [17].
A large number of patients in both groups retain good
visual acuity equal or better to 20/40, 124 eyes in group 1
and 140 eyes in second group. This result is in line with
other studies conducted earlier [5, 12]. Despite this
stratification, BCVA for both groups by age showed that
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37% of patients in age group 21–40 and 36% in age group
41–60 were registered as legally blind, indicating a strong
impact of monogenic retinal degenerations on incidence of
blindness principally in a productive age group.
Color perception problems didn’t appear to be a very
specific symptom in either group, since an equal number of
patients in both groups indicated presence and absence of
color vision problems. This is surprising, since color vision
discrimination problems should be more common in
primary diseases affecting central retina than in diseases
affecting periphery. This may be a consequence of the
“bystander effect”, when cones are effected secondarily
because of rod degeneration and production of rod-derived
cone viability factor (RdCVF) [11].
Usher syndrome I and II (34%), Stargardt disease (31%),
and choroideremia (14%) were the most frequent diagnoses
in our study. This corresponds to the results of other
studies, where Usher syndrome types I and II were found to
be the most frequent types of monogenic retinal dystrophies
in Germany and in Spain [1, 9, 10].
This study has some limitations. It was designed as a
retrospective cross-sectional study, and the data was obtained
from a clinical database which wasn’t initially designed for
research purposes. That limited us to the analysis of the data
that were available. Furthermore, the age of symptoms onset
estimation was based on the patients’ perception, and
therefore could be subjective. However, the current study
was based on clinical data obtained from the database and
included all patients with a diagnosis of interest, whereas the
study performed by Krumpatszky derived data from social
services and focused only on those patients that were already
registered as blind. Our study included a high percentage of
patients originating from other countries, which will make it
possible to more effectively compare with other non-German
studies performed in the future. Furthermore, examinations of
the patients from the study population were conducted by the
team of four senior resident ophthalmologists, who had
homogenous diagnosis criteria, which ensures high data
reliability.
Overall, the results of our study showed that these
monogenic retinal dystrophies are more frequent among
men than among women. We also found that relatively high
numbers of patients in both groups retained quite good
visual acuity, which shows that early and properly planned
rehabilitation strategies could be beneficial in order to
increase quality of life for these patients. Moreover, for
both groups an age for optimal therapeutic intervention was
defined. It is recommended that this should be taken into
account while screening for patients to take part in clinical
trials for testing new treatment strategies. It was also shown
in the study that color perception problems didn’t appear to
be a very specific symptom in both groups; this may be a
consequence of the “bystander effect”.
Furthermore, our study showed that the age of disease
onset can be estimated on the basis of an epidemiological
approach, which is based on epidemiological analysis of
age at main symptoms onset, derived from the history of
the disease, and main clinical parameters. An epidemiolog-
ical approach to the estimation of the disease onset could be
used by clinicians for detecting the duration of the disease
and its prognosis, planning rehabilitation measures, and for
researching the future possibilities for treatment. Further
long-term follow-up studies of clinical parameters are
needed for the establishment of a decision-making algo-
rithm for estimation of disease prognosis and rehabilitation
possibilities.
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